Pradaxa og Praxbind



Ca. 1-2 % av pasienter med atrieflimmer får hjerneinfarkt til tross for antikoagulasjon hvert år, og hvis man har tidligere slag, dobles risikoen.5

PRAXBIND reverserer Pradaxa før trombolyse – stadig mer erfaring i klinisk praksis.6 Pradaxa er den eneste NOAK med spesifikk antidot.1,7,8,12

Les mer om hvordan Praxbind virker

REFERANSER: 
  1. PRADAXA® SPC 19.10.2017.
  2. Connolly SJ et al. Dabigatran versus warfarin in patients with atrial fibrillation. NEJM 2009 Sep 17; 361:1139-1151 [Erratum: NEJM 2010 Nov 4; 363:1875-1876 and NEJM 2014 Oct 9; 371(15):1464-1465].
  3. Lip GY, Clemens A, Noack H et al. Patient outcomes using the European label for dabigatran. A posthoc analysis from the RE-LY database. Thromb Haemost 2014 May 5; 111(5):933-942.
  4. Halvorsen S, Ghanima W, Tvete IF et al. A nationwide registry study to compare bleeding rates inpatients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother (2017) 3 (1): 28-36
  5. Bushnell CD, Colon-Emeric CS: Secondary Stroke Prevention Strategies for the Oldest PatientsDrugs Aging. 2009; 26(3): 209–230
  6. Pikija S, Sztriha LK, Mutzenbach JS et al: Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence. CNS Drugs. 2017; 31(9): 747–757
  7. Pollack CV, Reilly PA, van Ryn J et al: Idarucizumab for Dabigatran Reversal — Full Cohort Analysis,. N Engl J Med 2017;377:431-44.1
  8. www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Atrial-Fibrillation-Management
  9. Xarelto® SPC 11/2017
  10. Eliquis® SPC 19.10.2017.
  11. Lixiana® SPC 17.07.2017
  12. Praxbind SPC 09.11.2017
  13. Kristoffer Andresen, Dan Atar, Erik Gjertsen, Waleed Ghanima, Svein Roseth & Odd Erik Johansen (2018): Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants, Scandinavian Cardiovascular Journal